-

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Mynaric AG (MYNA)

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Mynaric AG (“Mynaric” or the “Company”) (NASDAQ: MYNA). The investigation concerns whether Mynaric and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.

[Click here to learn more about the investigation]

On August 20, 2024, Mynaric issued a press release providing an update to its full-year 2024 guidance, advising that “the company now expects full-year 2024 IFRS-15 revenue to range between EUR 16.0 million to EUR 24.0 million compared to previous guidance of a range between EUR 50.0 million to EUR 70.0 million”, citing “production delays of CONDOR Mk3 caused by lower than expected production yields and component supplier shortages of key components”; and that “the company now expects full-year 2024 operating loss to range between a loss of EUR 55.0 million to EUR 50.0 million compared to previous guidance of a range between a loss of EUR 40.0 million to EUR 30.0 million”, citing “the lower than expected revenue and higher than expected production costs due to lower yields.” In a separate press release, Mynaric “announce[d] the voluntary departure of CFO Stefan Berndt von-Bülow for personal reasons, effective last week.” On this news, the price of Mynaric shares declined by $2.32 per share, or approximately 55.9%, from $4.15 per share on August 19, 2024 to close at $1.83 per share on August 20, 2024.

If you purchased or otherwise acquired Mynaric securities, have information, or would like to learn more about this investigation, contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this CONTACT FORM, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NASDAQ:MYNA

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

Kirby McInerney LLP Urges Investors in DoubleVerify Holdings, Inc. (DV) to Inquire About Their Rights in Class Action Lawsuit

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of the July 21, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of investors who acquired DoubleVerify Holdings, Inc. (“DoubleVerify” or the “Company”) (NYSE:DV) securities during the period from November 10, 2023, through February 27, 2025 (“the Class Period”). [LEARN MORE ABOUT THE CLASS ACTION] On February 28, 2024, DoubleVerify issued lower revenue growth e...

Kirby McInerney LLP Announces Creation of DOJ Antitrust Whistleblower Practice

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is pleased to announce that it has created a new practice group focused on supporting whistleblowers under the newly-announced U.S. Department of Justice’s Antitrust Division Whistleblower Rewards Program. The DOJ Antitrust Division’s Whistleblower Rewards Program offers rewards for individuals who report antitrust crimes and related offenses that harm consumers, taxpayers, and free market competition. Under the program rules, whist...

Kirby McInerney LLP Reminds Hims & Hers Health, Inc. (HIMS) Investors of Class Action Filing and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS) securities during the period of April 29, 2025, through June 23, 2025, inclusive (“the Class Period”). Investors have until August 25, 2025 to apply to the Court to be appointed as lead plaintiff i...
Back to Newsroom